ArticleInnovations in pharmacy2021

Efficacy and Safety of Innovative Experimental Chimeric Antigen Receptor (CAR) T-cells versus Axicabtagene ciloleucel (Yescarta) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL): Matching Adjusted Indirect Comparisons (MAICs) and Systematic Review.

Bayarmagnai Weinstein et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.